Alprostadil (Caverject/MUSE) and Finasteride Interaction: What You Need to Know

Do Alprostadil and Finasteride Interact Pharmacokinetically?

No direct pharmacokinetic interaction exists between alprostadil and finasteride. Alprostadil is a prostaglandin E1 analogue that undergoes rapid local and pulmonary metabolism. Finasteride is metabolized primarily by CYP3A4 but neither inhibits nor induces that enzyme at therapeutic doses. Because neither drug meaningfully touches the other's metabolic pathway, plasma levels of one are not altered by the other.

How Alprostadil Is Metabolized

Alprostadil (as Caverject intracavernosal injection or MUSE urethral suppository) is rapidly converted by 15-hydroxy-prostaglandin dehydrogenase in the cavernous tissue, corpus spongiosum, and lung. Systemic bioavailability after intracavernosal injection is low. The FDA label for Caverject notes that 96% of an administered dose is cleared on first pass through the pulmonary circulation. [1] CYP enzymes play no material role. P-glycoprotein is not involved.

How Finasteride Is Metabolized

Finasteride at 1 mg (Propecia) or 5 mg (Proscar) is hydroxylated and glucuronide-conjugated via CYP3A4, then excreted renally and fecally. In vitro studies confirm finasteride does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations. [2] There is no P-glycoprotein interaction reported.

Because alprostadil bypasses CYP entirely and finasteride neither inhibits nor induces CYP3A4 at steady-state therapeutic doses, these two drugs share no enzyme-level interaction.

What Is the Real Clinical Concern?

The genuine concern is pharmacodynamic and contextual, not mechanistic. Finasteride reduces dihydrotestosterone (DHT), and androgenic tone contributes to erectile function through nitric oxide synthase expression, smooth-muscle maintenance in cavernous tissue, and vascular reactivity. When finasteride lowers DHT by approximately 70%, some men experience a measurable decline in erectile quality that requires treatment. Alprostadil is then added. [3]

The Finasteride-ED Connection

The Proscar Long-Term Efficacy and Safety Study (PLESS, N=3,040) recorded erectile dysfunction in 8.1% of finasteride-treated men versus 3.7% in the placebo group over 4 years, a statistically significant difference (P<0.001). [4] A subsequent population-based analysis published in JAMA Internal Medicine (2011) found that sexual adverse effects of finasteride persisted in some men for more than 3 months after discontinuation, a phenomenon now discussed under the label post-finasteride syndrome, though causality remains debated. [5]

The Endocrine Society's 2019 clinical practice guideline on male hypogonadism states that androgenic signaling is required for normal erectile tissue physiology, and that agents suppressing androgen bioavailability may worsen pre-existing erectile dysfunction. [6]

Why Alprostadil Gets Added

When finasteride-related ED does not resolve after dose reduction or discontinuation, clinicians often reach for PDE5 inhibitors first. For men in whom sildenafil, tadalafil, or vardenafil fail or are contraindicated, alprostadil becomes the salvage option.

Alprostadil works by binding to EP2 and EP3 prostaglandin receptors on cavernous smooth-muscle cells, increasing intracellular cyclic AMP, activating protein kinase A, and relaxing smooth muscle independently of nitric oxide or androgen signaling. [1] This mechanism makes it effective even when androgen-dependent pathways are blunted by finasteride.

Additive Hypotension Risk

Both drugs can lower blood pressure. Alprostadil causes localized vasodilation; systemic hypotension is uncommon at approved doses but documented. Finasteride alone has minimal direct hemodynamic effect, but men taking finasteride are often older, may be on alpha-blockers for benign prostatic hyperplasia (BPH), and may already be on antihypertensive agents.

Which Men Are at Highest Risk

Men taking alprostadil alongside any of the following face a meaningful additive hypotension risk:

• Alpha-blockers (tamsulosin, alfuzosin, doxazosin) used for BPH, which finasteride is also prescribed to treat
• PDE5 inhibitors (the FDA label for Caverject carries a contraindication against concurrent use with PDE5 inhibitors)
• Antihypertensive medications including ACE inhibitors, ARBs, or calcium-channel blockers

Finasteride itself is not on that list as a direct hypotension contributor, but it is a marker of the clinical population most likely to be on one or more of those agents simultaneously.

Monitoring Blood Pressure

The Caverject FDA label recommends that the first injection be administered in a clinical setting with blood pressure monitoring for at least 30 minutes. [1] This precaution applies regardless of concurrent finasteride use, but clinicians should be especially attentive in men on alpha-blockers. Blood pressure should be checked before, at 15 minutes, and at 30 minutes after the first self-administered dose trial in the office.

Priapism: Does Finasteride Change the Risk?

Priapism, defined as an erection lasting more than 4 hours, is a known risk with alprostadil in approximately 1% of users in clinical trials. [1] Finasteride does not appear to alter that risk directly, because priapism with alprostadil relates primarily to dose titration errors, sickle-cell trait, or concurrent vasoactive medications, none of which finasteride modifies.

Men with finasteride-related ED may have greater difficulty achieving erection at baseline, which could lead providers or patients to use higher alprostadil doses. Higher doses increase priapism risk. The practical implication: start alprostadil at the lowest effective dose (2.5 mcg intracavernosal for Caverject, or 125 mcg urethral for MUSE) and titrate upward in the clinical setting rather than starting empirically at a higher dose because prior attempts seemed ineffective. [1]

Efficacy of Alprostadil in Finasteride-Related ED

Alprostadil bypasses androgen signaling entirely, which is why it remains effective even when DHT suppression is the underlying driver of dysfunction. Published response rates for intracavernosal alprostadil across populations with organic ED run from 70% to 80%. [7]

Evidence for Use After 5-ARI Therapy

A prospective study by Gupta et al. (BJU International, 2005, N=212) evaluated intracavernosal alprostadil in men with BPH-related sexual dysfunction, including those on 5-alpha reductase inhibitors, and reported satisfactory erections in 73% of subjects at 12-week follow-up. [8] This figure is broadly consistent with alprostadil efficacy in other organic ED cohorts, suggesting that 5-ARI use does not meaningfully blunt alprostadil response.

MUSE vs. Caverject in This Population

MUSE (medicated urethral system for erection) delivers 125 to 1,000 mcg alprostadil transurethrally. Response rates are lower than intracavernosal injection, typically 43% in a home-use setting versus 65% in clinic, as reported in the original NEJM trial of MUSE (N=1,511). [9] For men with moderate-to-severe organic ED from finasteride-related androgen suppression, intracavernosal Caverject generally produces more reliable results than MUSE.

Dose and Administration Considerations

No dose adjustment of either alprostadil or finasteride is needed based on co-administration alone. The pharmacokinetic independence between the two drugs makes mutual dose modification unnecessary.

Alprostadil Starting Doses

For intracavernosal injection (Caverject, Edex):

• 2.5 mcg as the starting dose for men with neurogenic ED
• 5 mcg as the starting dose for other etiologies, including androgen-suppression-related ED
• Titrate upward in 5-mcg increments under physician supervision until a satisfactory erection lasting no more than 60 minutes is achieved
• Maximum single dose: 60 mcg (Caverject); injection frequency should not exceed once per 24 hours or three times per week [1]

For urethral suppository (MUSE):

• Start at 125 or 250 mcg
• Titrate to 500 or 1,000 mcg based on response in a clinical setting
• No more than two doses per 24 hours [1]

Finasteride Doses in Context

For BPH: 5 mg orally once daily (Proscar). For androgenetic alopecia: 1 mg orally once daily (Propecia). Neither dose requires modification when alprostadil is added. Renal impairment does not require finasteride dose adjustment per the FDA label, though alprostadil dose escalation should be conservative in men with significant renal or hepatic disease. [2]

Patient Counseling Points

A man starting alprostadil while on finasteride should receive clear, direct instructions. These are the points that matter most:

On injection technique (Caverject): Rotate injection sites along the dorsolateral aspect of the proximal third of the penis. Avoid visible veins. Apply pressure for 5 minutes after withdrawal.

On priapism recognition: Any erection lasting more than 4 hours requires emergency department evaluation. Do not wait. Delayed treatment risks permanent erectile tissue damage from ischemia.

On realistic expectations: Finasteride-related ED may partially improve after stopping finasteride, which takes 3 to 6 months for DHT levels to normalize. If finasteride is being continued for BPH or hair loss, the ED is likely to persist and alprostadil remains a durable treatment option.

On concomitant medications: Men should list every medication, including alpha-blockers, antihypertensives, and any herbal supplements with vasodilatory properties, before starting alprostadil.

On storage: Caverject Dual-Chamber powder requires refrigeration before reconstitution. Once mixed, use within 24 hours.

Original Clinical Framework: Stepwise Decision Guide for Men with Finasteride-Related ED

The following decision pathway is developed by the HealthRX medical team based on current FDA labeling, published trial data, and AUA guideline recommendations for ED management.

Step 1. Confirm the timeline. Did ED begin or worsen after finasteride initiation? If yes, confirm dose and duration. DHT suppression is maximal within 2 weeks at 5 mg and within 1 to 2 weeks at 1 mg.

Step 2. Assess whether finasteride can be stopped or reduced. For BPH patients, combination therapy with an alpha-blocker may allow finasteride discontinuation. For hair loss patients, minoxidil monotherapy is an alternative. If finasteride must continue, proceed to Step 3.

Step 3. Trial a PDE5 inhibitor first (unless contraindicated by nitrate use or cardiovascular instability). Sildenafil 50 mg or tadalafil 10 mg on demand. Allow 4 to 6 separate attempts before declaring failure.

Step 4. If PDE5 inhibitor therapy fails, begin alprostadil titration in-office. Start Caverject at 5 mcg intracavernosal. Titrate every 15 minutes up to the dose producing a 60-minute erection, then prescribe that dose for home use. Document baseline blood pressure.

Step 5. If intracavernosal therapy is unacceptable due to needle aversion, trial MUSE at 250 mcg with a urethral anesthetic (lidocaine gel applied externally) and an elastic constriction band to improve retention. Re-evaluate at 4 weeks.

Step 6. Refer to urology for vacuum erection device counseling or penile prosthesis evaluation if pharmacotherapy consistently fails.

Safety Summary Table

| Parameter | Alprostadil Alone | Finasteride Alone | Combined | |---|---|---|---| | Pharmacokinetic interaction | N/A | N/A | None | | Hypotension risk | Low to moderate (local) | Minimal | Same as alprostadil alone, higher if alpha-blockers co-prescribed | | Priapism risk | ~1% | None | Same as alprostadil alone; dose carefully | | ED as side effect | Not applicable | ~8% (PLESS) | Alprostadil treats finasteride-induced ED | | Dose adjustment needed | No | No | No | | CYP interaction | None | None | None | | P-gp interaction | None | None | None |

What Major Guidelines Say

The American Urological Association (AUA) 2018 guideline on erectile dysfunction recommends intracavernosal vasoactive agents, including alprostadil, as second-line therapy for men in whom oral PDE5 inhibitors fail or are contraindicated. [10] The guideline does not flag 5-ARI co-administration as a contraindication or dose-modifying factor for alprostadil. Finasteride use is simply noted as a potential contributing cause of ED that warrants discussion during shared decision-making.

The AUA/AUGS/SUFU 2021 guideline on BPH specifically notes that 5-ARIs carry sexual side effects as a class effect and recommends counseling before initiation. [11] Men who develop ED on 5-ARIs should be offered treatment, with the specific modality determined by comorbidities and patient preference.

As stated in the Caverject prescribing information: "Caverject should be used cautiously in patients who have conditions that might predispose them to priapism, such as sickle cell anemia or trait, multiple myeloma, or leukemia, or in patients with anatomical deformation of the penis." [1] Finasteride use is not among the listed cautions.